End points for new agents in induction chemotherapy for locally advanced head and neck cancers. (Q34784828)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

0 references

1 reference

title

End points for new agents in induction chemotherapy for locally advanced head and neck cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

C Monnerat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

S Temam

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

J Bourhis

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

E Raymond

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 July 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

995-1006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12176777%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Radiation therapy alone or in combination with surgery in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Combination chemotherapy with vinblastine, bleomycin, and cis-diamminedichloroplatinum (II) in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Combination therapy of advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Induction chemotherapy in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Intra-arterial methotrexate chemotherapy and telecobalt therapy in cancer of the oral cavity and oropharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Induction chemotherapy in head and neck cancer: results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Induction chemotherapy in advanced head and neck tumors: results of two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

A randomized trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Chemotherapy in head and neck cancer. Overview of newer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Docetaxel: an active drug for squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF172